Abstract

Introduction: Vitamin D insufficiency (VDI) has been associated with increased cardiovascular risk in the non-HIV population. This study evaluates the relationship among serum 25-hydroxyvitamin D [25(OH)D] levels, cardiovascular risk factors, adipokines, antiviral therapy (ART) and subclinical atherosclerosis in HIV-infected males.

Methods: A cross-sectional study in ambulatory care was made in non-diabetic patients living with HIV. VDI was defined as 25(OH)D serum levels <75 nmol/L. Fasting lipids, glucose, inflammatory markers (tumour necrosis factor-α, interleukin-6, high-sensitivity C-reactive protein) and endothelial markers (plasminogen activator inhibitor-1, or PAI-1) were measured. The common carotid artery intima-media thickness (C-IMT) was determined. A multivariate logistic regression analysis was made to identify factors associated with the presence of VDI, while multivariate linear regression analysis was used to identify factors associated with common C-IMT.

Results: Eighty-nine patients were included (age 42 ± 8 years), 18.9% were in CDC (US Centers for Disease Control and Prevention) stage C and 75 were on ART. VDI was associated with ART exposure, sedentary lifestyle, higher triglycerides levels and PAI-1. In univariate analysis, VDI was associated with greater common C-IMT. The multivariate linear regression model, adjusted by confounding factors, revealed an independent association between common C-IMT and patient age, time of exposure to protease inhibitors (PIs) and impaired fasting glucose (IFG). In contrast, there were no independent associations between common C-IMT and VDI or inflammatory and endothelial markers.

Conclusions: VDI was not independently associated with subclinical atherosclerosis in non-diabetic males living with HIV. Older age, a longer exposure to PIs, and IFG were independent factors associated with common C-IMT in this population.

Keywords: atherosclerosis; vitamin D insufficiency; carotid intima media thickness; HIV; antiretroviral treatment; adipokines.

Introduction

Vitamin D insufficiency (VDI) is common in the general population [1]. Its estimated prevalence in people living with HIV is high, ranging from 70.3 to 83.7% [2,3]. Chronic inflammation due to HIV infection and altered vitamin D (VD) metabolism due to the use of some antiretroviral drugs have been associated with VDI in HIV-infected patients, who are also exposed to common factors related to VDI in the general population [2,3]. Recently, a EuroSIDA study has pointed to vitamin D deficiency (VDD) as an important co-factor in HIV disease progression and mortality, in the setting of widespread, efficient antiretroviral treatment (ART) [2].

The active metabolite of VD, 1,25 (OH)2 VD, is a steroid hormone that regulates the transcription of approximately 200 genes. Most of these genes are involved in calcium-bone homeostasis, immune function and the cardiovascular or metabolic system [4]. Large epidemiological studies and clinical trials have suggested some association between VDI (25(OH)D blood levels <75 nmol/L) and low bone mineral density, high blood pressure, depression, neurocognitive impairment, type 2 diabetes mellitus, metabolic syndrome, cancer and cardiovascular disease [4,5].

Several pathogenic mechanisms have been proposed to explain the role of VD levels in cardiovascular disease. VD influences endothelial and smooth muscle cell function by exerting antiproliferative effects on vascular smooth muscle [6] or mediating inflammation by lymphocyte and monocyte macrophage differentiation regulation and release of inflammatory cytokines [7]. VD also modulates the renin-angiotensin-aldosterone system [8]. Different authors have suggested that VD could protect against atherosclerosis, vascular calcification, arterial stiffness and endothelial dysfunction [9,10]. However, observational and interventional studies have yielded inconsistent results on the association of VDI to subclinical atherosclerosis and carotid intima-media thickness (C-IMT) in the general population and in patients living with HIV [11–13].
The aims of the present study are (1) to evaluate the prevalence of VDI in a population of men living with HIV and its association with cardiovascular risk factors, systemic inflammatory markers, lipodystrophy and ART exposure and (2) to determine whether VDI is associated with C-IMT after adjusting for other traditional and emergent cardiovascular risk factors in the HIV population.

Material and methods
A cross-sectional observational study was carried out in the Infectious Diseases and Endocrinology Units of a tertiary hospital in Alicante, Spain. The local Ethics Committee approved the study. All men living with HIV belonging to a cohort of 600 patients living with HIV, with regular assessment of endocrine parameters and cardiovascular risk, were proposed to participate in this study if they were ≥18 years of age, ART-naïve or on effective ART (<50 copies RNA/mL), with no changes in the previous six months. With respect to the gender of the study target population, only men were included because at the time of the execution of the study, we lacked a cohort of women with HIV infection with close monitoring of metabolic parameters. Only patients receiving two nucleoside reverse transcriptase inhibitors (NRTIs) with an enhanced protease inhibitor (PIs) or with a non-NRTI (efavirenz (EFV) or nevirapine) that never have been treated with PIs were included. Those with chronic hepatitis C, diabetes mellitus, active AIDS disease, active illegal drug use or psychiatric illness were excluded. No patients were receiving drugs containing calcium or VD. All patients gave written informed consent. The study was conducted in Alicante, Spain, a city on the southeastern Spanish Mediterranean coast (latitude 38° 23’ N) with more than 320 sunny days a year, between March 2009 and October 2010.

Participants were required to fast for 12 hours prior to the blood sample, which was performed between 8:00 and 9:00 AM. The samples were centrifuged, and serum and plasma were stored at −30°C until determination.

Outcome variables
25 (OH) VD levels
The serum 25(OH)D levels were determined using a Liaison® automatic chemiluminescence immunoassay analyser (DiaSorin, Stillwater, MN, USA). Total 25(OH)D: 25-OH-D2 + 25-OH-D3. Analytical sensitivity: 10 nmol/L. Intra-assay precision: up to 37 nmol/L, coefficient of variance (CV) 4.2%; and 157 nmol/L, CV 3.1%. Inter-assay precision: up to 37 nmol/L, CV 7.7%; and 157 nmol/L, CV 6.4%. The following definitions of VD status were used in this study: 25(OH)D sufficiency: ≥75 nmol/L (VDS); insufficiency: <75 nmol/L; deficiency (VDD): <50 nmol/L.

Secondary hyperparathyroidism was defined as serum 25(OH)D < 75 nmol/L and serum parathyroid hormone (PTH) > 65 pg/mL (6.9 pmol/L).

Subclinical atherosclerosis
Subclinical atherosclerosis was measured by evaluation of C-IMT, measured by ultrasonography (Hitachi EUB-5500HV), with a 7.5 MHz linear probe, using the Mannheim criteria [14]. Both common carotid arteries were evaluated, and IMT was measured automatically in the posterior wall at the end of

Table 1. Demographics, clinical and laboratory variables (n = 89)

| Variable                                | Value       |
|-----------------------------------------|-------------|
| Age, years; mean ± SD                  | 42 ± 8.2    |
| HIV clinical stage, n (%)              | A 53 (59.6) |
|                                        | B 19 (21.3) |
|                                        | C 17 (19.1) |
| Duration-HIV, years; mean ± SD         | 7.8 ± 5.6   |
| Nadir CD4+, cells/μL; median [P25–P75] | 204 [124–287] |
| Current CD4+, cells/μL; median [P25–P75]| 467 [364–677] |
| Treatment group, n (%)                 | Naïve 14 (15.7) |
|                                        | NNRTI 36 (40.4) |
|                                        | PI 39 (43.8) |
| Duration exposure, months; mean ± SD   | 67 ± 42     |
| Total ART                               | 36 ± 27     |
| NNRTI                                   | 111 ± 90*   |
| PI                                      | 55 ± 40     |
| Current exposure to ART (n = 75),%      | NRTI 34     |
|                                        | NNRTI 3     |
|                                        | PI 23       |
|                                        | Lopinavir 23|
|                                        | Atazanavir 10|
|                                        | Fosamprenavir 3|
|                                        | Tipranavir 3|
| Alcohol consumption (yes), n (%)        | 38 (42.7)   |
| Smoking, n (%)                          | Never smoker 23 (25.8) |
|                                        | Former smoker 12 (13.5) |
|                                        | Current smoker 54 (60.7) |
| Sedentary lifestyle (yes), n (%)        | 47 (58)     |
| Body-mass index, kg/m²; mean ± SD      | 24.8 ± 3.4  |
| Waist/Hip ratio; mean ± SD             | 0.95 ± 0.1  |
| Lipodistrophy (yes), n (%)             | 27 (30.7)   |
| IFG (yes), n (%)                        | 29 (32.6)   |
| Total cholesterol, mmol/L; mean ± SD   | 4.88 ± 1.09 |
| LDL-cholesterol, mmol/L; mean ± SD     | 3.26 ± 1.04 |
| HDL-cholesterol, mmol/L; mean ± SD     | 1.26 ± 0.37 |
| Triglycerides, mmol/L; median [P25–P75]| 1.65 [1.1–2.3] |
| 25-(OH)-D-D, mmol/L; mean ± SD         | 52.2 ± 27   |

CV, coefficient of variation; SD, standard deviation; n, number of patients; HIV-VL, HIV viral load; ART, antiretroviral treatment; non-NRTI group, current ART with 2 to 3 nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor (non-NRTI) and never received protease inhibitors (PIs); PI group, current ART with 2 to 3 NRTIs plus an enhanced PI; IFG, impaired fasting glucose (plasma glucose: 5.5 to 7 mmol/L); 25-(OH)-D, 25 hydroxy vitamin D; *sum of exposure.
diastole in a region free of plaque. The volume of interest has a length of 11 cm, adjustable to the visible IMT segment. The mean C-IMT was the mean value of the whole segment. The maximal C-IMT was the maximal value of the region of interest. The measurement was done automatically off-line with the Hitachi team software. Left and right common C-IMTs were evaluated separately, and bilateral C-IMT was obtained by the arithmetic mean of C-IMT of both sides. Results are expressed in millimetres.

Explanatory variables
As ART therapy can affect VD levels and subclinical atherosclerosis, patients were classified into three groups: (1) those who were naïve to ART; (2) the non-nucleoside group: EFV or nevirapine plus two or three NRTIs; and (3) the PI group: PI plus two or three NRTIs.

Lipid and carbohydrate metabolism variables: fasting glycaemia and basal lipid profile were measured; impaired fasting glucose (IFG) was defined as 5.5 to 7 mmol/L in at least two measurements; glucose was measured using the hexokinase method (Modular auto-analyzer; Roche Diagnostics, Grenzach, Germany), and lipid profile was measured by calorimetric enzymatic techniques (Modular auto-analyzer).

Systemic inflammatory markers: we measured high-sensitivity C-reactive protein (hsCRP) (turbidimetry kinetics; IMMAGE, Beckmann Coulter, Inc., Chasca, MN, USA), plasminogen activator inhibitor-1 (PAI-I), tumour necrosis factor-alpha (TNF-α), soluble forms of TNF-1 and -2 receptors and interleukin-6 (IL-6) (enzyme immunoassay; Quantikine, R&D Systems, Abingdon, UK). Lipodystrophy was determined using a standard questionnaire based on physical examination [15].

Table 2. Vitamin D insufficiency-associated factors: HIV clinical variable and ART

| VDI (:\<75 nmol/l) n = 72 | No VDI (:\>75 nmol/l) n = 17 | OR [IC95%] | p |
|---------------------------|----------------------------|------------|-----|
| Duration-HIV (years); mean ± SD | 7.7 ± 5.7 | 7.9 ± 5.4 | 0.99 [0.9–1.08] | 0.8 |
| CD4+ cells/μL; median [P25–P75] | 470 [368–689] | 442 [359–578] | 1.001 [0.9–1.003] | 0.3 |
| HIV-VL RNA/ml. <39, n (%) | 53 (73.6) | 11 (64.7) | 0.65 [0.2–2] | 0.4 |
| HIV-VL RNA/ml. (naïve patients); median [P25–75] | 20,100 [2910–44,684] | 21,900 [10,000–79,617] | 1 [1–1] | 0.4 |
| HIV clinical stage; n (%): | | | | |
| A | 40 (75) | 13 (25) | 0.2 |
| B | 18 (94) | 1 (6) | 5.8 [0.7–48.1] |
| C | 14 (82.3) | 3 (17.7) | 1.5 [0.37–6.1] |
| Treatment Group; n (%): | | | | |
| Naïve | 8 (57.1) | 6 (42.9) | 1 | 0.02 |
| NNRTI | 32 (88.8) | 4 (11.1) | 4.3 [1.3–15]* |
| PIs | 32 (65.3) | 7 (34.7) | |
| Duration of ART (months); mean ± SD | 66.8 ± 43.2 | 69.6 ± 37.4 | 0.99 [0.98–1.01] | 0.8 |
| Duration of PI (months); mean ± SD | 57 ± 41.8 | 43.8 ± 26.5 | 1.01 [0.9–1.03] | 0.4 |
| Duration of NNRTI (months); mean ± SD | 37 ± 27.7 | 31.1 ± 19.7 | 1.009 [0.98–1.03] | 0.5 |
| Lipodystrophy; % (n) | 31 (22) | 29.4 (5) | 1.1 [0.3–3.4] |

Explanatory variables with statistically significant results in unadjusted analysis and their significance are in bold. VDI, vitamin D insufficiency; SD, standard deviation; %, percentage; n, number of patients; HIV-VL, HIV viral load; ART, antiretroviral treatment; non-NRTI group, current ART with 2 to 3 nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor (non-NRTI) and never received protease inhibitors (Pis); PI group, current ART with 2 to 3 NRTIs plus an enhanced PI. *Naïve patients versus ART patients.
Table 3. Vitamin D insufficiency-associated factors: cardiovascular risk factors

|                      | VDI (≤ 75 nmol/l) | No VDI (≥ 75 nmol/l) | OR [IC95%] | \( p \) |
|----------------------|-------------------|----------------------|------------|--------|
| **Cardiovascular risk factors** |                   |                      |            |        |
| Age (years); mean ± SD | 42.8 ± 8.4        | 38.7 ± 7.1           | 1.07 [0.99–1.15] | 0.06   |
| High blood pressure% (n) | 47.2 (34)        | 35.3 (6)             | 1.6 [0.5–4.9] | 0.4    |
| Physical exercise (< 3 h/w) | 84.8 (56)        | 46.7 (7)             | 6.4 [1.9–21.6] | 0.03   |
| Smoker (yes) | 58.3 (42)        | 70.6 (12)            | 0.58 [0.18–1.8] | 0.35   |
| SBP (mmHg); mean ± SD | 127 ± 15         | 123 ± 12             | 1.02 [0.98–1.06] | 0.3    |
| DBP (mmHg); mean ± SD | 78 ± 10          | 72 ± 8              | 1.06 [0.99–1.11] | 0.06   |
| BMI (kg/m²); mean ± SD | 24.9 ± 3.4       | 23.9 ± 3.3           | 1.1 [0.9–1.2] | 0.2    |
| WHR                  | 0.95 ± 0.07      | 0.93 ± 0.07          | 44.5 [0.01–199,546] | 0.3    |
| Metabolic Syndrome% (n) | 34.7 (25)        | 11.8 (2)             | 3.9 [0.8–18.8] | 0.08   |
| **Metabolic parameters** |                   |                      |            |        |
| Fasting glycaemia (mmol/L); mean ± SD | 5.57 ± 0.57       | 5.11 ± 0.37         | 1.04 [0.9–1.09] | 0.2    |
| IFG [yes]; % (n) | 37.5 (27)        | 11.8 (2)             | 4.5 [0.96–21.2] | 0.057  |
| TC (mmol/L); mean ± SD | 4.96 ± 1.08      | 4.47 ± 1.1           | 1.01 [0.99–1.02] | 0.1    |
| LDLc (mmol/L); mean ± SD | 3.32 ± 1.06      | 3.1 ± 0.99           | 1.005 [0.99–1.02] | 0.4    |
| HDLc (mmol/L); mean ± SD | 1.25 ± 0.39      | 1.34 ± 0.26          | 0.98 [0.95–1.02] | 0.3    |
| TG (mmol/L); median [P25–P75] | 1.8 [1.39–2.45] | 0.99 [0.81–1.42] | 1.02 [1.007–1.03] | 0.002  |
| TG > 1.7 mmol/L | 56.9 (41)        | 11.8 (2)             | 9.9 [2.1–46.6] | 0.001  |
| Non-HDLc (mmol/L); mean ± SD | 3.7 ± 1.01       | 3.13 ± 1.03          | 1.015 [1.001–1.03] | 0.45   |
| Apolipoprotein B (g/L); mean ± SD | 0.88 ± 0.22      | 0.77 ± 0.2           | 12.6 [0.84–191] | 0.06   |
| **Inflammatory biomarkers** |                   |                      |            |        |
| hsCRP (mg/L); median [P25–P75] | 2.9 [0.14–0.57] | 1.9 [1.4–3.2]        | 7.43 [0.5–106.3] | 0.1    |
| PAI-1 (pg/L); mean ± SD | 9.6 ± 4         | 7.4 ± 2.4            | 1.22 [1.003–1.5] | 0.04   |
| TNF-α (pg/L); median [P25–P75] | 0.015 [0.01–0.01] | 0.015 [0.01–0.01] | 1.07 [0.89–1.28] | 0.46   |
| R1 TNF-α (pg/L); median [P25–P75] | 0.97 [0.85–1.12] | 0.92 [0.77–1.1]     | 1.001 [0.9–1.003] | 0.4    |
| R2 TNF-α (pg/L); median [P25–P75] | 1.89 [1.58–2.34] | 2.15 [1.77–2.79]    | 1 [0.9–1.002] | 0.2    |
| IL-6 (pg/L); median [P25–P75] | 0.003 [0.003–0.003] | 0.003 [0.003–0.003] | 1.16 [0.87–1.5] | 0.32   |

Explanatory variables with statistically significant results in unadjusted analysis and their significance are in bold. VDI, vitamin D insufficiency; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist-hip ratio; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; FG, fasting glucose; IFG, impaired fasting glucose (plasma glucose ≥ 5.55 mmol/L); TG, triglycerides; hsCRP, high-sensitivity C-reactive protein; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumour necrosis factor-alpha; R1 and R2, soluble forms of TNF-α receptors; IL-6, interleukin-6; IMT, intima-media thickness; CC, common carotid.

We also analyzed the effect of ART upon the VD levels. Patients receiving any ART combination had lower VD levels than naive patients (49 ± 26 vs. 71 ± 29 nmol/L, \( p < 0.01 \)). We observed differences in comparing treatment with PIs versus non-NRTIs (54 ± 29 vs. 43 ± 21 nmol/L, \( p = 0.06 \)), patients receiving EFV versus those with another third agent (43 ± 20 vs. 53 ± 29 nmol/L, \( p = 0.09 \)) and patients receiving lopinavir/rit versus those without such treatment (58 ± 33 vs. 45 ± 22 nmol/L, \( p = 0.05 \)).

VDI, HIV clinical variables and cardiovascular risk factors

We found a significant association between VDI and a sedentary lifestyle [OR: 6.4 (95% CI: 1.9 to 21.6)], and higher triglycerides concentrations (> 1.7 mmol/L) [OR: 9.9 (95% CI: 2.1 to 46.6)]. Although most of the inflammatory biomarkers were elevated in patients with VDI, only PAI-1 showed a significant association [OR: 1.22 (95% CI: 1.003 to 1.5)] (Table 3).

A multivariate logistic regression analysis that included both variables with significance in the bivariate analysis and
relevant clinical variables (age, duration of HIV, CD4 + count and CDC stage) was unable to identify any explanatory variable as an independent factor associated with the presence of VDI, with the exception of triglyceride concentration [OR: 1.02 (95% CI: 1.001 to 1.03, p = 0.04)].

On analyzing the correlation between VD concentrations and HIV clinical variables or cardiovascular risk factors, the only significant quantitative variables inversely associated with VD concentrations were triglycerides, R: -0.4 (p < 0.001); non-HDL cholesterol, R: -0.21 (p = 0.04); hsCRP, R: -0.22 (p = 0.04); and smoking (year/pack), R: -0.25 (p = 0.04).

VDI and subclinical atherosclerosis
In the univariate analysis, the presence of VDI was associated with greater common C-IMT (Figure 1). Patients with VDI were at a higher risk of having a maximum left C-IMT above median of the study population [OR: 3.2 (95% CI: 1.01 to 0.9), (p = 0.04)].

There was no correlation between common C-IMT and VD concentrations (as a parametric variable), though patients with VD concentrations below percentile 25 had an increased bilateral maximum common C-IMT (0.77 ± 0.11 vs. 0.71 ± 0.1, p = 0.06) and bilateral mean common C-IMT (0.63 ± 0.08 vs. 0.56 ± 0.06, p = 0.09).

The multivariate linear regression model, adjusted by confounding factors, revealed an independent association between patient age, time of exposure to PI and mean/maximum right common C-IMT. In turn, patient age and the presence of IFG were independently associated with mean/maximum left common C-IMT (Table 4). In contrast, there were no independent associations between common C-IMT and VDI or inflammatory and endothelial markers.

Discussion
A high prevalence of VDI (80.9%) has been found in this population of men living with HIV in a sunny Mediterranean city, in coincidence with observations in other studies in HIV.
Table 4. Variables predicting subclinical atherosclerosis in non-diabetic men with HIV infection

| Dependent variables | Mean right CC IMT | Maximum right CC IMT |
|---------------------|------------------|---------------------|
|                     | B | $r^2$ | p  | B | $r^2$ | p  |
| Mean left CC IMT    |   |       |   | Mean left CC IMT    |   |       |   |
|                     | B | $r^2$ | p  |                     | B | $r^2$ | p  |
| Age (10 years)      | 0.06 | 0.004 | <0.001 | 0.05 | 0.001 | 0.05 |
| Duration of HIV (years) | -0.07 | 0.2 |       | 0.07 | 0.2 |       |
| HIV-VL RNA/mL <39 cop.(yes) | 0.02 | 0.001 | 0.014 | 0.03 |
| PIs exposure (years) | 0.04 | 0.3 |       | 0.01 | 0.01 | 0.1 |
| NRTI exposure (years) | 0.006 | 0.3 |       | 0.01 | 0.01 | 0.35 |
| NNRTI exposure (years) | -0.03 | 0.4 | -0.01 | 0.8 |
| BMI (kg/m$^2$)      | -0.02 | 0.6 | -0.006 | 0.8 |
| WHR                 | -0.03 | 0.4 | -0.02 | 0.5 |
| Lipodystrophy (yes) | 0.067 | 0.2 | 0.01 | 0.3 |
| FG (mmol/L)         | 0.01 | 0.1 | 0.03 | 0.3 |
| hsRCP (mg/dL)       | -0.003 | 0.5 |       |       |
| PAI-1 (ng/L)        | 0.04 | 0.9 | -0.32 | 0.2 |
| IL-6 (pg/L)         | -0.03 | 0.4 | -0.02 | 0.5 |
| Vitamin D insufficiency (yes) | -0.00001 | 0.9 | 0.009 | 0.07 |
| IFG (yes)           | 0.006 | 0.2 | 0.009 | 0.07 |
| Constant            | 0.004 | 0.2 | 0.006 | 0.1 |
|                     | 0.01 | 0.8 | -0.04 | 0.39 |
| Median left CC IMT  | 0.46 | 0.12 | 0.77 | 0.02 |

Dependent variables are in bold; explanatory variables with statistically significant results in multiple regression analysis and their significance are in bold. CC, common carotid; IMT, intima-media thickness; B, standardized coefficient; $r^2$, coefficient of determination; BMI, body mass index; WHR, waist-hip ratio; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; FG, fasting glucose; IFG, impaired fasting glucose (plasma glucose ≥5.55 mmol/L); TG, triglycerides; hsRCP, high-sensitivity reactive C protein; PAI-1, plasminogen activator inhibitor-1; IL-6, interleukin 6.
populations [2,3,16-18]. Twenty-five per cent of the patients with VDI also had elevated PTH concentrations, indicative of severe VD deficiency – this being a situation not previously reported.

In coincidence with other authors, we observed an association between low VD concentrations and antiretroviral therapy, especially EFV [3,16,19-22]. EFV induces 24-hydroxylase, an enzyme of the CYP-P450 complex which hydrolyzes 25(OH)D to the inactive metabolite of VD, 24,25(OH)2D, reducing the concentrations of the active metabolite of VD [23]. Other variables of HIV infection, such as the nadir or basal CD4+ counts, HIV viral load, previous AIDS, clinical stage, lipodystrophy or years with HIV infection, were not associated with VDI, as was noted in the EuroSIDA study [2].

A significant association between VDI and C-IMT was observed in the univariate analysis. But multivariate analysis was unable to confirm such an independent association between VDI and an increase in common C-IMT. Only older age, IFG and treatment with PI were independently associated with subclinical atherosclerosis. In contrast to our results, two cross-sectional studies have reported an independent association between VDI and C-IMT in people living with HIV in the multivariate regression analysis [12,13]. The clinical characteristics of the population, the study design, the methodology and the explanatory variables included in the regression analysis could explain differences among studies.

Observational and interventional studies yield inconsistent data on the association between VD and subclinical atherosclerosis markers such as C-IMT and cardiovascular disease in the general population [10,24]. Two randomized, double-blind, placebo-controlled trials have shown no improvement in endothelial function, arterial stiffness or inflammation markers after VD supplementation in the general population [25] and in people living with HIV [26]. In the EuroSIDA cohort study, involving 1985 patients with five years of follow-up, lower VD concentrations were not associated with increasing incidences of cardiovascular disease [2].

People living with HIV have greater C-IMT [27] and an increased risk of cardiovascular disease and myocardial infarction compared with matched non-HIV controls [28]. The possible relationship between ART and cardiovascular disease is controversial [29-32]. Our study found an independent association between common C-IMT and patient age, IFG and time of exposure to PI (increase of 0.1 mm in C-IMT if IFG exists, or for every five years of PI treatment). In the general population, the adjusted relative risk of stroke is increased by 18% per 0.1 mm increase in C-IMT, and the risk of myocardial infarction is increased by 15% [33,34]. Previous studies have described an accelerated progression of atherosclerosis in patients living with HIV with cumulative exposure to PI therapy [30,35,36]. In subjects without HIV and without diabetes, the presence of glucose intolerance (IFG or impaired glucose tolerance) is associated with a significant increase in C-IMT [37,38]. This is the first time that such an association is reported in non-diabetic men living with HIV.

Our study has some limitations. Its cross-sectional, observational design precludes definitive conclusions regarding the causal relationships, only associations. Also, we have not included a control group without HIV infection and we have not evaluated solar exposure, seasonal factor or VD intake from food sources. The use of specific markers to monitor chronic inflammation, such as alpha-1 acid glycoprotein, increases in which are more associated with early and late convalescence, may change the correlation between VD insufficiency and inflammatory markers. On the other hand, the study also has several unique strengths: we measured C-IMT, which is a strong and sensitive surrogate marker of the earliest changes of atherosclerosis, and we made a careful assessment of several potential confounders of the C-IMT and VD status relationship, adjusting for traditional and emergent cardiovascular risk factors.

Conclusions
In summary, we have observed a high prevalence of VDI in a population of men living with HIV in a sunny Mediterranean city. Older age, a longer exposure to PIs, and IFG are independent factors associated with subclinical atherosclerosis measured by C-IMT in males living with HIV and with low cardiovascular risk. Therefore, our data suggest that patients living with HIV who are exposed to PI, especially older individuals or those with impaired glucose metabolism, are at special atherosclerosis risk.

VDI is associated with other cardiovascular risk factors and could behave as a surrogate marker of subclinical atherosclerosis in non-diabetic males living with HIV. Hence, the role of VD in atherosclerosis, if any, remains elusive and poorly defined, and preventive interventions should focus on traditional cardiovascular risk factors. Probably only prospective studies with clinical endpoints will give a definitive answer.

Authors’ affiliations
1Infectious Diseases Unit, Alicante University General Hospital-FISABIO, Alicante, Spain; 2Clinical Medicine Department, Miguel Hernández University, Campus of San Juan, San Juan de Alicante, Alicante, Spain; 3Endocrinology and Nutrition Department, Alicante University General Hospital-FISABIO, Alicante, Spain; 4Neurology Department, San Carlos Clinic Hospital, Madrid, Spain; 5Hormone Laboratory, Alicante University General Hospital-FISABIO, Alicante, Spain; 6Preventive Medicine Department, Alicante University General Hospital-FISABIO, Alicante, Spain

Competing interests
The authors have no competing interests to declare.

Authors’ contributions
OMP, JP, AP and VB: study design, researched data, analysis and interpretation of data, and drafting of the manuscript. EM, SR, CE and LG: researched data. RA: supervision-analytical sample collection, and processing of biological samples obtained. JSP: study design and analysis, and interpretation of data. CSC: ultrasonography image processing and analysis. All authors reviewed the article for important intellectual content and final approval.

Funding
This work was supported by the Spanish Foundation for Research and Prevention of AIDS (grant no. FIPSE 246400/07) and from the Carlos III Institute (grant no. FIS PI100430). This work has been (partially) funded by the RD06/006/1008 and RD12/0017 projects as part of the Plan Nacional R + D + I and cofinanced by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).
References

1. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(1):353–73.
2. Viard JP, Souberbielle JC, Kirk O, Reeke J, Knyz B, Losso M, et al. EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011;25:1305–15.
3. Dao CN, Patel P, Overtont ET, Rameie F, Pals SL, Johnson C, et al. Study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN) investigators. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52:396–405.
4. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364:248–54.
5. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.
6. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis. 2006;186:20–8.
7. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13:621–9.
8. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the rennin angiotensin system. J Clin Invest. 2002;110:229–38.
9. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, et al. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009;120:687–98.
10. Giallauro F, Milaneschi Y, Tanaka T, Maggio M, Canepa M, Elango P, et al. Arterial stiffness and vitamin D levels: the Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2012;97:3717–23.
11. Auber P, Bontoli M, Pozz C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2:76–89.
12. Ross AC, Judd S, Kumari M, Hileman C, Storer N, Labbato D, et al. Vitamin D deficiency is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923–8.
13. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regimen change: results from the MDNET trial. AIDS Res Hum Retroviruses. 2011;27:29–34.
14. Yin M, Stein M. The effect of antiretrovirals on vitamin D. Clin Infect Dis. 2011;52:406–8.
15. Carrelli AL, Walker MD, Lowe H, McMahon DJ, Rundek T, Sacco RL, et al. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. Stroke. 2011;42:2240–5.
16. Gepner AD, Ramamurthy R, Krueger DC, Korczak CE, Binkley N, Stein JH. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One. 2012;7:e36617.
17. Longenecker CT, Hileman CG, Carman TL, Ross AC, Seydafiian S, Brown TT, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17:613–21.
18. Mangili A, Polak JF, Skinner SC, Gerrior J, Sheehan H, Harrington A, et al. HIV infection and progression of carotid and coronary atherosclerosis: the CARE study. J Acquir Immune Defic Syndr. 2011;58:148–53.
19. Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med. 2009;17:98–103.
20. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-collaboration cohort. Lancet. 2008;371:1417–26.
21. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35.
22. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regimen change: results from the MDNET trial. AIDS Res Hum Retroviruses. 2011;27:29–34.
23. Yi JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Chaisson LE, et al. Progression of carotid artery intima-media thickness in HIV-infected and uninfected adults. AIDS. 2007;21:1137–45.
24. Lundgren JD, Neumann H, Babiker A, Cooper D, Delpreuz D, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients: Strategies for Management of Anti-Retroviral Therapy (INSIGHT), DAD Study Group. AIDS. 2008;22:F17–24.
25. Van den Oord SC, Sijbrands EJ, Ten Kate GL, van Kleren D, van Domburg RT, van der Steen AF, et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. Atherosclerosis. 2013;228:1–11.
26. Lorenz MW, Markus HS, Bols ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:659–67.
27. Maggi P, Lillo A, Perilli F, Masarei R, Chirinian A. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS. 2004;18:1023–8.
28. Sankatsing RR, Wirt FW, Vogel M, de Groot E, Brinkman K, Rockstroh JK, et al. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis. 2009;202(2):589–95.
29. Viscozzi G, Andreozzi P, Marigliano V. Associations of plasma glucose levels and traits of metabolic syndrome with carotid intima media thickness in nondiabetic elderly subjects: are they mediated by insulin resistance? Metab Syndr Relat Disord. 2013;11:41–5.
30. Zhang YJ, Hong J, Zhan WW, Li XY, Gu WQ, Yang YS, et al. Hyperglycaemia after glucose loading is a major predictor of preclinical atherosclerosis in nondiabetic subjects. Clin Endocrinol. 2006;66:153–7.